Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
Horizon Discovery Group PLC
of the United Kingdom
sales of £36.51 million [US$46.51 million]
of which 62%
Eczacibasi Ilac Sanayi ve T.A.S.
(597.91 million Turkish Liras [US$112.26 million]
of which 71%
was Health), and
Moberg Pharma AB (publ)
based in Sweden
(439.03 million Swedish Kronor [US$48.89 million]
of which 35%
was Kerasal Nail /Nalox).
During the year ended December of 2017, sales at
Valneva SE were 105.29 million Euro (US$119.38 million).
increase of 11.9%
versus 2016, when the company's sales were 94.06 million Euro.
This was the fifth consecutive year of sales increases at Valneva SE
(and since 2012, sales have increased a total of 2,969%).
Sales of Technologies and Services saw an increase
that was more than double the company's growth rate: sales were up
33.7% in 2017, from
6.99 million Euro to 9.35 million Euro.
Not all segments of Valneva SE experienced an increase in sales in 2017:
sales of Vaccine Candidates fell 25.7% to 7.50 million Euro.